Antiphospholipid antibodies and the risk of severe and non-severe pre-eclampsia: The NOHA case-control study

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 4, 2016, Pages 675-684

  Marchetti, T ^a   de Moerloose, P ^a   Gris, J C ^b  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b NÎMES UNIVERSITY HOSPITAL   (France)

Author keywords

Antibodies anticardiolipin; Antibodies antiphospholipid; Beta 2 glycoprotein I; Lupus anticoagulant; Pre eclampsia

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHATIDYLSERINE ANTIBODY; PHOSPHOLIPID ANTIBODY; PROTEIN ANTIBODY; PROTHROMBIN COMPLEX ANTIBODY; UNCLASSIFIED DRUG; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN; IMMUNOGLOBULIN G; PHOSPHATIDYLSERINE; PROTHROMBIN;

ADULT; AGE; ARTICLE; BLOOD SAMPLING; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DELIVERY; DISEASE SEVERITY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MULTIPARA; NON SEVERE PREECLAMPSIA; OBESITY; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN DOMAIN; SEVERE PREECLAMPSIA; SMOKING; ANTIPHOSPHOLIPID SYNDROME; BLOOD; CHEMISTRY; COMPLICATION; HELLP SYNDROME; HYPERTENSION; IMMUNOLOGY; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; RISK; TREATMENT OUTCOME;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; CARDIOLIPINS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HELLP SYNDROME; HUMANS; HYPERTENSION; IMMUNOGLOBULIN G; LUPUS COAGULATION INHIBITOR; MIDDLE AGED; PHOSPHATIDYLSERINES; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PROTEIN DOMAINS; PROTHROMBIN; RISK; TREATMENT OUTCOME;

EID: 84962577179     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13257     Document Type: Article

References (37)

1. Ghulmiyyah L, Sibai B. Maternal mortality from preeclampsia/eclampsia. Semin Perinatol 2012; 36: 56-9.
2. Moodley J. Maternal deaths associated with hypertensive disorders of pregnancy: a population-based study. Hypertens Pregnancy 2004; 23: 247-56.
3. Chappell LC, Enye S, Seed P, Briley AL, Poston L, Shennan AH. Adverse perinatal outcomes and risk factors for preeclampsia in women with chronic hypertension: a prospective study. Hypertension 2008; 51: 1002-9.
4. Marchetti T, Cohen M, de Moerloose P. Obstetrical antiphospholipid syndrome: from the pathogenesis to the clinical and therapeutic implications. Clin Dev Immunol 2013; 2013: 159124.
5. Marchetti T, Cohen M, Gris JC, de Moerloose P. Diagnosis and management of obstetrical antiphospholipid syndrome: where do we stand? Pol Arch Med Wewn 2013; 123: 713-20.
6. de Groot PG, Meijers JC. beta(2) -Glycoprotein I: evolution, structure and function. J Thromb Haemost 2011; 9: 1275-84.
7. De Groot PG, Meijers JC, Urbanus RT. Recent developments in our understanding of the antiphospholipid syndrome. Int J Lab Hematol 2012; 34: 223-31.
8. Nodler J, Moolamalla SR, Ledger EM, Nuwayhid BS, Mulla ZD. Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: analysis of a population-based hospital dataset. BMC Pregnancy Childbirth 2009; 9: 11.
9. Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, Ramire de Jesus G, Erkan D. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res (Hoboken) 2013; 65: 1869-73.
10. de Groot PG, Urbanus RT. The significance of autoantibodies against beta2-glycoprotein I. Blood 2012; 120: 266-74.
11. de Laat B, Pengo V, Pabinger I, Musial J, Voskuyl AE, Bultink IE, Ruffatti A, Rozman B, Kveder T, de Moerloose P, Boehlen F, Rand J, Ulcova-Gallova Z, Mertens K, de Groot PG. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009; 7: 1767-73.
12. Mahler M, Norman GL, Meroni PL, Khamashta M. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev 2012; 12: 313-7.
13. Pengo V, Ruffatti A, Tonello M, Cuffaro S, Banzato A, Bison E, Denas G. Padayattil Jose S. Antibodies to Domain 1 (Dm1) of beta2-Glycoprotein 1 (beta2GP1) correctly classify patients at risk in Antiphospholipid Syndrome (APS). J Thromb Haemost 2015; 13: 782-7.
14. Zigon P, Cucnik S, Ambrozic A, Kveder T, Semrl SS, Rozman B, Bozic B. Detection of antiphosphatidylserine/prothrombin antibodies and their potential diagnostic value. Clin Dev Immunol 2013; 2013: 724592.
15. Hoxha A, Ruffatti A, Mattia E, Meneghel L, Tonello M, Salvan E, Pengo V, Punzi L. Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome. Clin Chem Lab Med 2015; 53: 1265-70.
16. Lissalde-Lavigne G, Fabbro-Peray P, Cochery-Nouvellon E, Mercier E, Ripart-Neveu S, Balducchi JP, Daurès JP, Perneger T, Quéré I, Dauzat M, Marès P, Gris JC. Factor V Leiden and prothrombin G20210A polymorphisms as risk factors for miscarriage during a first intended pregnancy: the matched case-control 'NOHA first' study. J Thromb Haemost 2005; 3: 2178-84.
17. Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thromb Haemost 1995; 74: 1597-603.
18. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, De Groot PG; Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7: 1737-40.
19. Fontana P, Poncet A, Lindhoff-Last E, de Moerloose P, Devreese KM. Refinement of the cutoff values of the HemosIL AcuStar assay for the detection of anticardiolipin and anti-beta2 glycoprotein-1 antibodies. J Thromb Haemost 2014; 12: 2034-7.
20. Audibert F, Friedman SA, Frangieh AY, Sibai BM. Clinical utility of strict diagnostic criteria for the HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. Am J Obstet Gynecol 1996; 175: 460-4.
21. Wisser J, Dirschedl P, Krone S. Estimation of gestational age by transvaginal sonographic measurement of greatest embryonic length in dated human embryos. Ultrasound Obstet Gynecol 1994; 4: 457-62.
22. Salomon LJ, Duyme M, Crequat J, Brodaty G, Talmant C, Fries N, Althuser M. French fetal biometry: reference equations and comparison with other charts. Ultrasound Obstet Gynecol 2006; 28: 193-8.
23. ACOG technical bulletin. Hypertension in pregnancy. Number 219-January 1996 (replaces no. 91, February 1986). Committee on Technical Bulletins of the American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 1996; 53: 175-83.
24. Ros HS, Cnattingius S, Lipworth L. Comparison of risk factors for preeclampsia and gestational hypertension in a population-based cohort study. Am J Epidemiol 1998; 147: 1062-70.
25. Rand JH, Wolgast LR. Dos and don'ts in diagnosing antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program 2012; 2012: 455-9.
26. Al-Balushi MS, Hasson SS, Said EA, Al-Busaidi JZ, Al-Daihani MS, Othman MS, Sallam TA, Idris MA, Al-Kalbani M, Woodhouse N, Al-Jabri AA. Fluctuation in the levels of immunoglobulin M and Immunoglobulin G Antibodies for Cardiolipin and beta2-Glycoprotein among healthy pregnant women. Sultan Qaboos Univ Med J 2014; 14: e478-85.
27. Chauleur C, Galanaud JP, Alonso S, Cochery-Nouvellon E, Balducchi JP, Mares P, Fabbro-Peray P, Gris JC. Observational study of pregnant women with a previous spontaneous abortion before the 10th gestation week with and without antiphospholipid antibodies. J Thromb Haemost 2010; 8: 699-706.
28. Bouvier S, Cochery-Nouvellon E, Lavigne-Lissalde G, Mercier E, Marchetti T, Balducchi JP, Marès P, Gris JC. Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood 2014; 123: 404-13.
29. Lockshin MD, Kim M, Laskin CA, Guerra M, Branch DW, Merrill J, Petri M, Porter TJ, Sammaritano L, Stephenson MD, Buyon J, Salmon JE. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012; 64: 2311-8.
30. Nelson DB, Ziadie MS, McIntire DD, Rogers BB, Leveno KJ. Placental pathology suggesting that preeclampsia is more than one disease. Am J Obstet Gynecol 2014; 210: e1-7.
31. Boyd HA, Tahir H, Wohlfahrt J, Melbye M. Associations of personal and family preeclampsia history with the risk of early-, intermediate- and late-onset preeclampsia. Am J Epidemiol 2013; 178: 1611-9.
32. Machado JS, Machado MS, Bertagnolli TV, Duarte G, Sandrim VC, Cavalli RC. [108-POS]: Assessment of concentrations of sFlt-1 and PlGF as predictors of preeclampsia. Pregnancy Hypertens 2015; 5: 58.
33. Liu Y, Zhao Y, Yu A, Zhao B, Gao Y, Niu H. Diagnostic accuracy of the soluble Fms-like tyrosine kinase-1/placental growth factor ratio for preeclampsia: a meta-analysis based on 20 studies. Arch Gynecol Obstet 2015; 292: 507-18.
34. Carroll TY, Mulla MJ, Han CS, Brosens JJ, Chamley LW, Giles I, Pericleous C, Rahman A, Sfakianaki AK, Paidas MJ, Abrahams VM. Modulation of trophoblast angiogenic factor secretion by antiphospholipid antibodies is not reversed by heparin. Am J Reprod Immunol 2011; 66: 286-96.
35. Akhter E, Shums Z, Norman GL, Binder W, Fang H, Petri M. Utility of antiphosphatidylserine/prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus. J Rheumatol 2013; 40: 282-6.
36. Erkan D, Derksen WJ, Kaplan V, Sammaritano L, Pierangeli SS, Roubey R, Lockshin MD. Real world experience with antiphospholipid antibody tests: how stable are results over time? Ann Rheum Dis 2005; 64: 1321-5.
37. Gris JC, Mercier E, Quere I, Lavigne-Lissalde G, Cochery-Nouvellon E, Hoffet M, Ripart-Neveu S, Tailland ML, Dauzat M, Marès P. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103: 3695-9.